Breaking News

Cleveland BioLabs Shifts Focus to Clinical Development

October 18, 2013

Transfers lab and preclinical services personnel to Buffalo BioLabs

Cleveland BioLabs, Inc. has changed its operational focus as a result of its maturing development pipeline and a reduced need for lab and preclinical services. The company has transferred its lab and preclinical services personnel to Buffalo BioLabs, LLC, an entity affiliated with one of the company's co-founders, Andrei Gudkov, Ph.D., D. Sci. Cleveland BioLabs has executed a service agreement for continued access to this team on an as-needed basis.
"As we noted on our second quarter call, our maturing product pipeline requires less laboratory and preclinical support. We believe this restructuring allows us to sharpen our clinical development focus and preserve financial resources, while maintaining priority access to existing laboratory and preclinical services talent," said Yakov Kogan, Ph.D., chief executive officer of Cleveland BioLabs.

Related Compliance:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.